Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the ...
US stocks end up with S&P 500 and Dow gaining on the week. Focus returns to the economy and tariffs. FedEx and Nike fall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback